Preparing for serendipity

Same author

Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans.

The Journal of clinical investigation·2025

Same author

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

The Journal of clinical investigation·2025

Same author

A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus.

Journal of cellular physiology·2024

Same author

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma.

Acta neuropathologica communications·2024

Same author

MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.

Proceedings of the National Academy of Sciences of the United States of America·2023

Same journal

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

Cancer biology & therapy·2026

Same journal

NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Cancer biology & therapy·2026

Same journal

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026

Same journal

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Cancer biology & therapy·2026

Same journal

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Cancer biology & therapy·2026

Same journal

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Cancer biology & therapy·2026

Related Experiment Videos

Preparing for serendipity

Related Concept Videos

Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.

Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus.

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma.

MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

Related Experiment Videos

Preparing for serendipity

Related Concept Videos

Related Articles

Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.

Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus.

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma.

MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.